Literature DB >> 24717798

Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus.

Peter S Lee1, Nobuko Ohshima2, Robyn L Stanfield3, Wenli Yu3, Yoshitaka Iba2, Yoshinobu Okuno4, Yoshikazu Kurosawa2, Ian A Wilson1.   

Abstract

Influenza viruses present a significant health challenge each year, as in the H3N2 epidemic of 2012-2013. Here we describe an antibody, F045-092, that possesses broadly neutralizing activity against the entire H3 subtype and accommodates the natural variation and additional glycosylation in all strains tested from 1963 to 2011. Crystal structures of F045-092 in complex with HAs from 1975 and 2011 H3N2 viruses reveal the structural basis for its neutralization breadth through insertion of its 23-residue HCDR3 into the receptor-binding site that involves striking receptor mimicry. F045-092 extends its recognition to divergent subtypes, including H1, H2 and H13, using the enhanced avidity of its IgG to overcome lower-affinity Fab binding, as observed with other antibodies that target the receptor-binding site. This unprecedented level of antibody cross-reactivity against the H3 subtype can potentially inform on development of a pan-H3 vaccine or small-molecule therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24717798      PMCID: PMC4358779          DOI: 10.1038/ncomms4614

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  63 in total

1.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

2.  The influenza virus resource at the National Center for Biotechnology Information.

Authors:  Yiming Bao; Pavel Bolotov; Dmitry Dernovoy; Boris Kiryutin; Leonid Zaslavsky; Tatiana Tatusova; Jim Ostell; David Lipman
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

3.  A common solution to group 2 influenza virus neutralization.

Authors:  Robert H E Friesen; Peter S Lee; Esther J M Stoop; Ryan M B Hoffman; Damian C Ekiert; Gira Bhabha; Wenli Yu; Jarek Juraszek; Wouter Koudstaal; Mandy Jongeneelen; Hans J W M Korse; Carla Ophorst; Els C M Brinkman-van der Linden; Mark Throsby; Mark J Kwakkenbos; Arjen Q Bakker; Tim Beaumont; Hergen Spits; Ted Kwaks; Ronald Vogels; Andrew B Ward; Jaap Goudsmit; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-11       Impact factor: 11.205

4.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

5.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16.

Authors:  Marie Pancera; Syed Shahzad-Ul-Hussan; Nicole A Doria-Rose; Jason S McLellan; Robert T Bailer; Kaifan Dai; Sandra Loesgen; Mark K Louder; Ryan P Staupe; Yongping Yang; Baoshan Zhang; Robert Parks; Joshua Eudailey; Krissey E Lloyd; Julie Blinn; S Munir Alam; Barton F Haynes; Mohammed N Amin; Lai-Xi Wang; Dennis R Burton; Wayne C Koff; Gary J Nabel; John R Mascola; Carole A Bewley; Peter D Kwong
Journal:  Nat Struct Mol Biol       Date:  2013-05-26       Impact factor: 15.369

8.  Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children.

Authors:  Iain Stephenson; Jane Democratis; Angie Lackenby; Teresa McNally; James Smith; Manish Pareek; Joanna Ellis; Alison Bermingham; Karl Nicholson; Maria Zambon
Journal:  Clin Infect Dis       Date:  2009-02-15       Impact factor: 9.079

9.  Update: Influenza activity - United States, September 30, 2012-February 9, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-02-22       Impact factor: 17.586

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  93 in total

1.  Structural basis for Marburg virus neutralization by a cross-reactive human antibody.

Authors:  Takao Hashiguchi; Marnie L Fusco; Zachary A Bornholdt; Jeffrey E Lee; Andrew I Flyak; Rei Matsuoka; Daisuke Kohda; Yusuke Yanagi; Michal Hammel; James E Crowe; Erica Ollmann Saphire
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

2.  Diverse antigenic site targeting of influenza hemagglutinin in the murine antibody recall response to A(H1N1)pdm09 virus.

Authors:  Jason R Wilson; Zhu Guo; Wen-Pin Tzeng; Rebecca J Garten; Xu Xiyan; Elisabeth G Blanchard; Kristy Blanchfield; James Stevens; Jacqueline M Katz; Ian A York
Journal:  Virology       Date:  2015-08-27       Impact factor: 3.616

3.  Unique Structural Features of Influenza Virus H15 Hemagglutinin.

Authors:  Netanel Tzarum; Ryan McBride; Corwin M Nycholat; Wenjie Peng; James C Paulson; Ian A Wilson
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

4.  Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites.

Authors:  Katie L Winarski; Natalie J Thornburg; Yingchun Yu; Gopal Sapparapu; James E Crowe; Benjamin W Spiller
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

5.  Structure of the apo anti-influenza CH65 Fab.

Authors:  Peter S Lee; Ashley J Arnell; Ian A Wilson
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-01-28       Impact factor: 1.056

Review 6.  Influenza virus antigenicity and broadly neutralizing epitopes.

Authors:  Gillian M Air
Journal:  Curr Opin Virol       Date:  2015-04-04       Impact factor: 7.090

Review 7.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

Review 8.  Structural insights into the design of novel anti-influenza therapies.

Authors:  Nicholas C Wu; Ian A Wilson
Journal:  Nat Struct Mol Biol       Date:  2018-02-02       Impact factor: 15.369

9.  Structure and receptor binding of the hemagglutinin from a human H6N1 influenza virus.

Authors:  Netanel Tzarum; Robert P de Vries; Xueyong Zhu; Wenli Yu; Ryan McBride; James C Paulson; Ian A Wilson
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

10.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.